Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis

Name: Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis
Published: 2017
License: Public Domain

University Hospital, Clermont-Ferrand · 2017

ClinicalTrials.gov · Datasets · License: Public Domain · 2017

Open Source ↗

hepatitis-c

chronic hcv infection, hepatitis c, genotype 1b, non severe fibrosis, treatment naïve, 8 weeks of treatment, elbasvir/grazoprevir combination, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis

Related documents